natgillin/translations-raw huggingface dataset:
- The powder vial contains 75 mg aztreonam (as lysine).
- Viala s praškom vsebuje 75 mg aztreonama (kot lizin).
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CAYSTON OUTER CARTON (With a Blue Box - Not for co-packaging with the Altera Nebuliser Handset)
CAYSTON ZUNANJA ŠKATLA (Vključno z »blue box« podatki - Ni za skupno pakiranje s kompletom z nebulatorjem Altera)
Cayston is not for use in children under the age of 6 years.
Otroci, mlajši od 6 let, ne smejo uporabljati zdravila Cayston.
Cayston is a white to off-white powder and solvent for nebuliser solution.
Zdravilo Cayston je bel do sivkasto bel prašek in vehikel za inhalacijsko raztopino za nebulator.
How to take Cayston using the Altera Nebuliser Handset
Kako uporabljati zdravilo Cayston s kompletom z nebulatorjem Altera
Continue to inhale and exhale comfortably until the treatment is finished.
Ne dihajte skozi nos. Sproščeno vdihujte in izdihujte do konca zdravljenja.
County Cork
Carrigtohill County Cork Irska
Powder vial and solvent ampoule:
Viala s praškom in ampula z vehiklom:
An association between persistent isolation of MRSA and worse clinical outcome has been reported in the literature.
V literaturi poročajo o povezavi med persistentno izolacijo bakterije MRSA in poslabšanjem kliničnega izida.
Each 28-day course of Cayston was followed by a 28-day off drug period.
Vsakemu 28-dnevnemu ciklu zdravljenja je sledilo 28-dnevno obdobje brez jemanja zdravila.
Cayston should only be reconstituted with the solvent provided.
Zdravilo Cayston se lahko rekonstituira samo s priloženim vehiklom.
For the combined Phase 3 placebo-controlled studies, ten minutes following a single dose of 75 mg inhaled aztreonamon Days 0, 14, and 28, the mean sputum concentrations in 195 patients with CF were 726 µg/g, 711 µg/g, and 715 µg/g, respectively, indicating no increased accumulation of aztreonam following repeated dosing.
14., in 28. dan srednje koncentracije v izpljunku pri 195 bolnikih s CF 726 µg/g, 711 µg/g oz. 715 µg/g, kar kaže, da ni povečane akumulacije aztreonama po večkratni uporabi.
Individual patients' sputum aztreonam concentrations exhibited considerable variability.
Koncentracije aztreonama v izpljunku posameznih bolnikov so kazale velika nihanja.
The emergence of parenteral P. aeruginosa resistance to aztreonam or other beta-lactam antibiotics may have potential consequences for the treatment of acute pulmonary exacerbations with systemic antibiotics.
Pojavnost parenteralne odpornosti povzročitelja P. aeruginosa na aztreonam ali druge betalaktamske antibiotike ima lahko potencialne posledice na zdravljenje akutnega poslabšanja pljučne simptomatike s sistemskimi antibiotiki.
Powder and solvent for nebuliser solution 42 single-use vials
prašek in vehikel za inhalacijsko raztopino za nebulator 42 vial za enkratno uporabo 44 1-ml ampul vehikla za enkratno uporabo
The emergence of parenteral P. aeruginosa resistance to aztreonam and other beta-lactam antibiotics may have potential consequences for the treatment of acute pulmonary exacerbations with systemic antibiotics.
Pojav parenteralne odpornosti povzročitelja P. aeruginosa na aztreonam in druge betalaktamske antibiotike ima lahko potencialne posledice za zdravljenje akutnega poslabšanja pljučne simptomatike s sistemskimi antibiotiki.
Powder and solvent for nebuliser solution 84 single-use vials
prašek in vehikel za inhalacijsko raztopino za nebulator 84 vial za enkratno uporabo 88 1-ml ampul vehikla za enkratno uporabo
Powder vial also contains L-Lysine Solvent ampoule contains sodium chloride, water for injections
Ampula z vehiklom vsebuje natrijev klorid, vodo za injekcije.
In a 24-week active-controlled study of Cayston therapy, no increases in P. aeruginosa MIC50 (± 2 dilution change) were observed, whereas MIC90 increased to 4 times the initial MIC. At the end of the study, the percentage of patients with aztreonam MIC for P. aeruginosa above the parenteral breakpoint (> 8 µg/ml) increased from 34% at baseline to 49%, the percentage of patients with P. aeruginosa resistant to at least 1 betalactam antibiotic increased from 56% at baseline to 67%, and the percentage of patients with P. aeruginosa resistant to all 6 beta-lactam antibiotics tested increased from 13% at baseline to 18%.
(> 8 µg/ml) povečal z izhodiščnih 34 % na 49 %, odstotek bolnikov s povzročiteljem P. aeruginosa, odpornim na vsaj 1 betalaktamski antibiotik, se je povečal z izhodiščnih 56 % na 67 % in odstotek bolnikov s povzročiteljem P. aeruginosa, odpornim na vseh 6 betalaktamskih antibiotikov, se je povečal z izhodiščnih 13 % na 18 %.Obstaja nevarnost, da izolati povzročitelja P. aeruginosa razvijejo odpornost proti aztreonamu ali drugim betalaktamskim antibiotikom pri bolnikih, zdravljenih z zdravilom Cayston.
In contrast, the serum concentration of aztreonam following administration of aztreonam for injection (500 mg) is approximately 54 µg/ml.
Za primerjavo je koncentracija aztreonama v serumu po uporabi aztreonama za injiciranje (500 mg)
Each powder vial contains 75 mg aztreonam.
Ena viala s praškom vsebuje 75 mg aztreonama.
How to store Cayston
Shranjevanje zdravila Cayston
No dose adjustment is necessary in cases of hepatic impairment.
Pri okvarjenem delovanju jeter ni treba prilagajati odmerka.
Do not mix Cayston with any other medicines in the Altera Nebuliser Handset.
Zdravila Cayston ne mešajte z drugimi zdravili v kompletu z nebulatorjem Altera.
Keep the handset level.
- Navodilo shranite.
Hepatic impairment
Okvarjeno delovanje ledvic
Put the prepared Cayston solution in the Altera Nebuliser Handset (see below).
Pripravljeno raztopino zdravila Cayston vstavite v komplet z nebulatorjem Altera (glejte spodaj).
Respiratory, thoracic and mediastinal disorders: Very common:
Bolezni dihal, prsnega koša in mediastinalnega prostora:
CP-AI-006 was an open-label follow-on study to CP-AI-005 and CP-AI-007 evaluating the safety of repeated exposure to aztreonamand the effect on disease-related endpoints over multiple 28-day courses.
Študija CP-AI-006 je bila odprta študija, ki je bila podaljšek študij CP-AI-005 in CP-AI-007.
The co-primary endpoints were non-inferiority of Cayston to TNS in relative change from baseline to Day 28 in FEV1 % predicted and superiority of Cayston to TNS in actual change from baseline in
Primarna opazovana cilja sta bila enakovrednost zdravila Cayston glede na RTN glede relativne spremembe od izhodišča na 28. dan za napovedani odstotek FEV1 % in prednost zdravila Cayston glede na RTN pri dejanski spremembi od izhodišča za napovedani odstotek FEV1 % v 3 ciklih zdravljenja (povprečje dejanske spremembe napovedanega odstotka FEV1 % ob koncu vsakega cikla zdravljenja).
If you are using other inhaled therapies to treat cystic fibrosis, the recommended order of use is as follows:
Če jemljete druga inhalacijska zdravila za zdravljenje cistične fibroze, se priporoča naslednji vrstni red uporabe: bronhodilatator mukolitiki (zdravilo, ki pomaga pri topljenju goste sluzi, ki se ustvarja v pljučih)
Investigations: Common:
Preiskave:
Mean peak plasma levels at Days 0, 14, and 28 of a course with 75 mg inhaled aztreonam 3 times a day were 0.55 µg/ml, 0.67 µg/ml, and 0.65 µg/ml, respectively, indicating no systemic accumulation of aztreonam following 3 times a day dosing.
0,67 µg/ml in 0,65 µg/ml, kar kaže, da ni sistemske akumulacije aztreonama po uporabi trikrat na dan.
- Do not put the intravenous (injectable) form of aztreonam in the Altera Nebuliser Handset.
- V komplet z nebulatorjem Altera ne dajajte aztreonama za intravensko uporabo (za injiciranje).
EU/1/09/543/001: 28-day pack of Cayston EU/1/09/543/002: 28-day pack of Cayston plus one Altera Nebuliser Handset
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/09/543/002: 28-dnevni paket zdravila Cayston in en komplet z nebulatorjem Altera
Cayston 75 mg powder and solvent for nebuliser solution.
Cayston 75 mg prašek in vehikel za inhalacijsko raztopino za nebulator.
One amber-coloured vial of Cayston with a blue cap.
Potrebujete naslednje: eno rjavkasto vialo z zdravilom Cayston z modro zaporko.
Using the Altera Nebuliser to take your Cayston
Priprava nebulatorja Altera za uporabo zdravila Cayston
After reconstitution, each ml of the nebuliser solution contains 75 mg aztreonam (as lysine).
Po rekonstituciji vsebuje en mililiter inhalacijske raztopine za nebulator 75 mg aztreonama (v obliki lizina).
The reconstituted Cayston is then poured into the Altera Nebuliser Handset and the dose administered.
Rekonstituirano zdravilo Cayston vlijte v komplet z nebulatorjem Altera in uporabite odmerek.
Cayston 75 mg powder for nebuliser solution aztreonam
Cayston 75 mg prašek za inhalacijsko raztopino za nebulator aztreonam
After reconstitution the nebuliser solution contains 75 mg aztreonam.
Po rekonstituciji vsebuje inhalacijska raztopina za nebulator 75 mg aztreonama.
Cayston should not be mixed with any other medicinal products in the Altera Nebuliser Handset.
Cayston ne mešajte z drugimi zdravili v kompletu z nebulatorjem Altera.
- Do not put other medicines in the Altera Nebuliser Handset.
- V komplet z nebulatorjem Altera ne dajajte drugih zdravil.
Uncommon:
Zelo pogosti:
- Joint pain - Lower lung function test results
- izpuščaj - bolečina v sklepih
Cayston 75 mg powder and solvent for nebuliser solution aztreonam
Cayston 75 mg prašek in vehikel za inhalacijsko raztopino za nebulator aztreonam
Common side effects (affects 1 to 10 users in 100) - Difficulty breathing - Chest discomfort - Runny nose - Coughing up blood - Rash
- nelagodje v prsnem košu - nahoden nos - izkašljevanje krvi
Cayston may be taken in repeated cycles of 28 days on therapy followed by 28 days off Cayston therapy.
Zdravilo Cayston se lahko uporablja v ponavljajočih 28-dnevnih ciklih zdravljenja, ki jim sledi 28
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Cayston VIAL LABEL
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
Do not put other medicinal products in the Altera Nebuliser Handset.
V komplet z nebulatorjem Altera ne dajajte drugih zdravil.
Step A: With the blue cap tab facing toward you, place the vial on a flat surface.
Korak A: Postavite vialo na ravno površino, tako da je jeziček modre zaporke obrnjen proti vam.
If you plan to breast-feed ask your doctor for advice before taking Cayston.
Če nameravate med uporabo zdravila Cayston dojiti, se posvetujte s svojim zdravnikom.
Renal and hepatic impairment
Bolniki z okvarjenim delovanjem ledvic in jeter
lung function test decreased1 1 See section Description of selected adverse reactions
1 Glejte poglavje Opis posameznih neželenih učinkov
Aztreonamtherapy resulted in significant improvements in pulmonary function and respiratory symptoms at Day 28 in the 66 patients treated with one course Cayston 75 mg 3 times a day.
Pri 66 bolnikih, ki so prejemali en cikel zdravljenja z aztreonamom 75 mg 3-krat na dan, je zdravljenje povzročilo pomembno izboljšanje pljučne funkcije in respiratornih simptomov na 28. dan.
The four additional solvent ampoules are provided in case of spillage.
Dodane so štiri ampule z vehiklom za primer, da se katera polije.
What Cayston is and what it is used for What you need to know before you take Cayston How to take Cayston
Kaj morate vedeti, preden boste uporabili zdravilo Cayston
Entry criteria included CF, FEV1 ≤ 75% predicted, stable pulmonary disease, a recent positive sputum culture for P. aeruginosa, and previous treatment with aerosolised antibiotics without demonstration of drug intolerance.
Merila za sodelovanje so vključevala CF, napovedani odstotek FEV1 ≤ 75 %, stabilno pljučno bolezen,
whereas MIC90 increased intermittently to 4 times the initial MIC.
Niso opazili povečanja MIK50 (± 2 spremembi v redčenju) za povzročitelja P. aeruginosa, pri čemer se je povečanje MIK90 pokazalo v prehodnem 4-kratnem povečanju začetne MIK.
Powder and solvent for nebuliser solution.
prašek in vehikel za inhalacijsko raztopino za nebulator Bel do sivkasto bel prašek.
Pulmonary function and respiratory symptoms significantly improved from baseline to Day 28 in patients treated with one course of Cayston.
Pri bolnikih, ki so prejeli en cikel zdravljenja z zdravilom Cayston, so se pljučna funkcija in respiratorni simptomi pomembno izboljšali od izhodiščne točke do 28. dneva.
A decrease in P. aeruginosa susceptibility to aztreonam and other beta-lactam antibiotics was observed in clinical studies of Cayston.
V kliničnih študijah z zdravilom Cayston so opazili zmanjšanje občutljivosti povzročitelja P. aeruginosa na aztreonam in druge betalaktamske antibiotike.
Always take this medicine exactly as your doctor has told you.
Pri uporabi tega zdravila natančno upoštevajte navodila zdravnika.
Renal impairment
- vnetje žrela
Open the ampoule of solvent by twisting off the tip.
Zasukajte vrh in tako odprite ampulo z vehiklom.
A total of 137 paediatric patients aged 6 to 17 years with chronic P. aeruginosa infection and FEV1 ≤ 75% predicted have received Cayston in Phase 2 and Phase 3 clinical studies (6-12 years, n = 35; 13-17 years, n = 102).
≤ 75% (6-12 let, n = 35; 13-17 let, n = 102).
administration.
uporabi.
Package leaflet: Information for the user Cayston 75 mg powder and solvent for nebuliser solution
Navodilo za uporabo Cayston 75 mg prašek in vehikel za inhalacijsko raztopino za nebulator aztreonam
This summary was last updated in 03-2013.
Povzetek je bil nazadnje posodobljen 03-2013.
EMA/190324/2013 EMEA/H/C/001098
EMA/238944/2013EMA/238944/2013 EMEA/H/C/001098
Because pantoprazole has been in use for many years, the applicant presented data from the scientific literature.
Ker je pantoprazol v uporabi že več let, je predlagatelj predstavil podatke iz znanstvene literature.
It is available as gastroresistant tablets (20 mg).
Na voljo je v obliki gastrorezistenčnih tablet (20 mg).
Pantoprazole-containing medicines have been available in the European Union (EU) since 1994.
Zdravila, ki vsebujejo pantoprazol, so v Evropski uniji (EU) na voljo od leta 1994 naprej.
The patient may need to take the medicine for two to three days in a row for symptoms to improve.
Bolnik bo morda moral zdravilo jemati dva do tri dni zapored, da se simptomi izboljšajo.
The full EPAR for Somac Control can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Somac Control je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The main measure of effectiveness was the number of patients with symptoms of heartburn over the first two weeks of treatment.
Glavno merilo učinkovitosti je bilo število bolnikov s simptomi zgage v prvih dveh tednih zdravljenja.
Patients should not take the medicine for longer than four weeks without consulting their doctor.
Bolniki zdravila ne smejo jemati dlje kot štiri tedne brez posveta pri zdravniku.
The recommended dose of Somac Control is one tablet once a day until symptoms have stopped.
Priporočeni odmerek zdravila Somac Control je ena tableta enkrat na dan, dokler simptomi ne izzvenijo.
The tablets should be swallowed whole with liquid before a meal and should not be chewed or crushed.
Tablete se pogoltnejo cele s tekočino pred obrokom in se ne smejo žvečiti ali zdrobiti.
The European Commission granted a marketing authorisation valid throughout the EU for Somac Control on 12 June 2009.
Evropska komisija je dovoljenje za promet z zdravilom Somac Control, veljavno po vsej Evropski uniji, odobrila dne 12. junija 2009.
Somac Control is similar to a ‘reference medicine' already authorised in the European Union (EU) called Somac.
Zdravilo Somac Control je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Somac.
The most common side effects with Somac Control (seen in around 1 patient in 100) are diarrhoea and headache.
Najpogostejša neželena učinka zdravila Somac Control (opažena pri približno 1 bolniku od 100) sta driska in glavobol.
If there is no improvement in symptoms within two weeks of continuous treatment, patients should consult their doctor.
Če v dveh tednih neprekinjenega zdravljenja ne pride do izboljšanja simptomov, naj se bolnik posvetuje z zdravnikom.
‘Gastroresistant' means that the tablet's contents pass through the stomach without being broken down until they reach the intestine.
Izraz „gastrorezistenten“ pomeni, da vsebina tablet preide skozi želodec in se ne razgradi, dokler ne doseže črevesa.
This is a summary of the European public assessment report (EPAR) for Somac Control.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Somac Control.
For more information about treatment with Somac Control, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Somac Control preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Somac Control must not be used in people who are hypersensitive (allergic) to pantoprazole, soya or any of the other ingredients.
Zdravila Somac Control ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) pantoprazol, sojo ali katero koli drugo sestavino zdravila.
The medicine can be obtained without a prescription.
Izdaja zdravila je brez recepta.
The applicant also presented information from two main studies looking at the effects of pantoprazole 20 mg in a total of 563 adults who had symptoms of acid reflux, including at least one episode of heartburn in the three days before the studies began.
Prav tako je predstavil podatke iz dveh glavnih študij, v katerih so učinke pantoprazola v odmerku 20 mg proučevali pri skupno 563 odraslih, ki so imeli simptome kislega refluksa in vsaj eno epizodo zgage v treh dneh pred začetkom študije.
What benefit has Somac Control shown during the studies?
Kakšne koristi je zdravilo Somac Control izkazalo med študijami?
In the first study, 74% of the patients taking pantoprazole (80 out of 108) and 43% of those taking placebo (48 out of 111) had no heartburn after two weeks.
V prvi študiji 74 % (80 od 108) bolnikov, ki so jemali pantoprazol, in 43 % (48 od 111) tistih, ki so jemali placebo, po dveh tednih ni imelo simptomov zgage.
The CHMP therefore decided that Somac Control's benefits are greater than its risks and recommended that it be given marketing authorisation.
Zato je zaključil, da so koristi zdravila Somac Control večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Somac Control.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Somac Control, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
In the second study, 70% of the patients taking pantoprazole (121 out of 172) and 59% of those talking ranitidine (102 out of 172) had no heartburn after two weeks of treatment.
V drugi študiji 70 % (121 od 172) bolnikov, ki so jemali pantoprazol, in 59 % (102 od 172) tistih, ki so jemali ranitidin, po dveh tednih zdravljenja ni imelo simptomov zgage.
It is used for long-term treatments and is also used to treat a wider range of gastrointestinal diseases (conditions affecting the gut) than Somac Control.
Uporablja se za dolgotrajno zdravljenje in za zdravljenje širšega spektra bolezni prebavil (stanj, ki prizadenejo črevesje) kot zdravilo Somac Control.
It works by blocking ‘proton pumps', proteins found in specialised cells in the stomach lining that pump acid into the stomach.
Deluje tako, da zavira „protonske črpalke“, tj. beljakovine v posebnih celicah v želodčni sluznici, ki črpajo kislino v želodec.
Somac Control is used for the short-term treatment of the symptoms of acid reflux in adults.
Zdravilo Somac Control se uporablja za kratkotrajno zdravljenje simptomov kislega refluksa pri odraslih.
The CHMP noted that pantoprazole 20 mg was effective in the short-term treatment of reflux symptoms and that there is a long safety experience with the medicine as a prescription medicine.
Odbor za zdravila za uporabo v humani medicini (CHMP) je ugotovil, da je pantoprazol v odmerku 20 mg učinkovit pri kratkotrajnem zdravljenju simptomov refluksa in da obstajajo dolgotrajne izkušnje glede varne uporabe tega zdravila, ki se izdaja na recept.
Somac Control is a medicine that contains the active substance pantoprazole.
Zdravilo Somac Control je zdravilo, ki vsebuje zdravilno učinkovino pantoprazol.
Other information about Somac Control
Druge informacije o zdravilu Somac Control:
It must not be used with atazanavir (a medicine used to treat human immunodeficiency virus [HIV] infection).
Zdravilo Somac Control se ne uporabljati z atazanavirjem (zdravilom za zdravljenje okužbe z virusom človeške imunske pomanjkljivosti [HIV]).
The first study compared pantoprazole with placebo (a dummy treatment) in 219 adults, and the second compared it with ranitidine (another medicine used to treat acid reflux symptoms) in 344 adults.
V prvi študiji so pri 219 odraslih primerjali pantoprazol s placebom (zdravilom brez zdravilne učinkovine), v drugi pa pri 344 odraslih učinke pantoprazola z ranitidinom (drugim zdravilom za zdravljenje simptomov kislega refluksa).
Acid reflux is when acid produced in the stomach escapes into the gullet, causing heartburn and acid regurgitation (acid flowing up into the mouth).
Kisli refluks je vračanje kisline, ki se tvori v želodcu, v požiralnik, kar povzroča zgago ter regurgitacijo kisline (dviganje kisline proti ustom).
Pantoprazole was also more effective than placebo at reducing symptoms of acid regurgitation.
Pantoprazol je bil učinkovitejši od placeba tudi pri lajšanju simptomov regurgitacije kisline.
For the full list of all side effects reported with Somac Control, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi pantoprazola, glejte navodilo za uporabo.
What is the risk associated with Somac Control?
Kakšna tveganja so povezana z zdravilom Somac Control?
This prevents the active substance from being destroyed by the acid in the stomach.
S tem se prepreči, da bi kislina v želodcu razgradila zdravilno učinkovino.
The reference medicine, Somac, is only available with a prescription.
Referenčno zdravilo Somac se izdaja le na recept.
The active substance in Somac Control, pantoprazole, is a proton pump inhibitor.
Zdravilna učinkovina zdravila Somac Control, pantoprazol, je zaviralec protonske črpalke.
By blocking the pumps, pantoprazole reduces acid production, relieving the symptoms of acid reflux.
Pantoprazol z zaviranjem črpalk zmanjša nastajanje kisline in s tem lajša simptome kislega refluksa.
Why has Somac Control been approved?
Zakaj je bilo zdravilo Somac Control odobreno?
Pantoprazole was more effective than placebo and ranitidine at improving the symptoms of acid reflux.
Pantoprazol je bil pri izboljšanju simptomov kislega refluksa učinkovitejši od placeba in ranitidina.
It was also of the opinion that, based on the experience of the use of pantoprazole, the availability of
Menil je tudi, da je glede na izkušnje z uporabo pantoprazola dostopnost zdravila Somac Control brez medicinskega nadzora ustrezna.
What is Somac Control?
Kaj je zdravilo Somac Control?
How has Somac Control been studied?
Kako je bilo zdravilo Somac Control raziskano?
What is Somac Control used for?
Za kaj se zdravilo Somac Control uporablja?
How is Somac Control used?
Kako se zdravilo Somac Control uporablja?
How does Somac Control work?
Kako zdravilo Somac Control deluje?
What is the outcome of the review?
Kakšen je izid pregleda?
The review of Diotop was initiated at the request of the United Kingdom, under Article 29(4) of Directive 2001/83/EC.
Pregled zdravila Diotop se je začel na zahtevo Združenega kraljestva v skladu s členom 29(4) Direktive 2001/83/ES.
Why was Diotop reviewed?
Zakaj je bilo zdravilo Diotop pregledano?
What is Diotop?
Kaj je zdravilo Diotop?